Sectors
Generali Insurance, Miele and Barmer Gek are among the limited partners that backed the first close of the fund, which is expected to reach $135m in size.
Genetic testing technology producer Singlera Genomics has attracted $20m in a series A round led by a subsidiary of Eli Lilly.
Nutritional ingredient developer Puro, launched last month by an ex-Torrent executive, has received $37m in funding from the conglomerate.
The digital health fund, launched by Astellas Pharma and MPM Capital late last month, will initially look to invest up to $6m in two to three deals per year.
The Maabarot-backed oral insulin developer has closed a $30m round featuring WuXi PharmaTech that will fund trials for two disorders.
Cancer care technology developer Avelas has now raised about $35m altogether, after Pharmstandard led a series C round also featuring Alexandria and WuXi PharmaTech.
Tioma Therapeutics, an oncology treatment developer, previously known as Vasculox, has secured funding from backers including Novo, GlaxoSmithKline and Roche.
Alps Electric and PICC made strategic investments as part of a round that boosted the total raised by Neusoft's medical services spinout to more than $230m.
Precision medicine developer Metabolon has now raised $80m since 2000, and its earlier investors include Sumitomo and Syngenta.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
